Leiden, The Netherlands, Nov. 7, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the successful enrollment of the 100th patient into the Natural History Study of Duchenne muscular dystrophy (DMD). The goal of this observational study is… Continue reading Prosensa Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy
Author: Willem van Lawick
Kiadis Pharma Secures Manufacturing Services Agreement for its Phase II Clinical Program with Blood Cancer Treatment ATIR™ with the German Red Cross Blood Donor Service
Amsterdam, The Netherlands, October 7, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that a Services Agreement has been signed with the German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS) whereby GRCBDS will provide pharmaceutical development and GMP manufacturing services for Kiadis Pharma’s ongoing Phase II… Continue reading Kiadis Pharma Secures Manufacturing Services Agreement for its Phase II Clinical Program with Blood Cancer Treatment ATIR™ with the German Red Cross Blood Donor Service
GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy
LONDON and LEIDEN, Netherlands, Sept. 20, 2013 (GLOBE NEWSWIRE) — GlaxoSmithKline (GSK) and Prosensa today announced that GSK’s Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6… Continue reading GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy
Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™ and Study Meets Primary Objective ~ 67% survival demonstrated after 5 years and no transplant related mortalities ~
Amsterdam, The Netherlands, September 11, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that the five-year follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR™ over a broad dose range. ATIR™ is a cell-based product designed… Continue reading Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™ and Study Meets Primary Objective ~ 67% survival demonstrated after 5 years and no transplant related mortalities ~
Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053
Leiden, The Netherlands, Sept. 6, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the dosing of the first patient in its Phase I/II clinical trial of PRO053, an exon-skipping compound for the treatment of Duchenne muscular dystrophy… Continue reading Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053
